Valeo Pharma has announced the launch of the Enerzair Breezhaler indacaterol / glycopyrronium / mometasone furoate and Atectura Breezhaler indacaterol / mometasone furoate DPIs in Canada. The company acquired Canadian rights to the two Novartis dry powder inhalers in March 2021. Enerzair (QVM149) and Atectura (QMF149) are also approved in Europe and in Japan.
Valeo CEO Steve Saviuk commented, “The commercial launch of Enerzair Breezhaler and Atectura Breezhaler is a key milestone for Valeo. It marks the debut of the company’s commercial efforts in the $700M Canadian asthma market, one of Canada’s largest therapeutic segments. I am especially proud of our Valeo team that organized this major product launch less than three months after licensing the products from Novartis Pharmaceuticals Canada Inc.”
President and Chief Operating Officer Frederic Fasano added, “We are very excited to start promoting and selling our first respiratory products. The establishment of our country wide respiratory, medical and commercial infrastructure is well under way and it is driven by a team of highly skilled and experienced pharma professionals. Nelly Komari, a seasoned pharma executive, has recently joined Valeo to lead the medical team in support of our asthma product launches. Enerzair Breezhaler and Atectura Breezhaler have demonstrated, against the current standard of care, that they improve the level of control of asthma symptoms and better prevent the related complications. Our team is very excited to start to reach out to clinicians to introduce both products and is proud to provide Canadian patients with these new treatment options.”
Read the Valeo Pharma press release.
